A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer

Introduction We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy. Case Presentation A 70‐year‐old man with relapsed metastatic castration‐sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m 2 ). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post‐treatment, the patient remained in a stable condition without any signs of PSA recurrence. Conclusion This case highlights the potential of triplet therapy as a highly effective treatment strategy for high‐risk mCSPC patients who experience recurrence after initial local therapy.